close icon

Bank of America Riding the Earnings Wave… For Now.

The last time we wrote about Bank of America was on October 18th, 2018. The stock was trading below $29 a share, down from the $33.05 top reached in March.

The bank had just reported a record first quarter, but the stock price was falling nevertheless. So in order to make sense of it, we turned to Elliott Wave analysis of BAC’s 3-hour chart, shown below.

Bank of America stock Elliott Wave prediction

The chart revealed that the decline from $33.05 was a simple A-B-C zigzag correction with an expanding triangle in wave B and wave C still under construction. This meant more weakness could be expected in wave C, but a bullish reversal should be expected as soon as it ended.

In terms of price, we thought “BAC may slide to $26 – $25 a share, before the situation starts to improve.” The bulls actually took the wheel at $22.66 on December 24th.

Yesterday, the stock rose by over 7% and closed at $28.45. This time, the market’s reaction to Bank of America’s record Q4 report was unanimously positive.

Bank of America climbs 7% after record Q4 earnings

The fact that the bullish reversal occurred over 20 days ago once again proves that “the habit of the market is to anticipate, not to follow.” The market was anticipating investors’ positive reaction to the bank’s earnings report.

Now, once a correction is over, the larger trend resumes. BAC was clearly in an uptrend prior to March, 2018, and the decline from $33.05 to $22.66 is corrective. So, we can expect this positive reaction to continue and eventually lift the stock to a new high.

Bank of America – The Bigger Picture

However, in less than a year Bank of America demonstrated that record profits don’t always translate into a rising stock price. Besides, simply extrapolating the current trend of rising earnings into the future to justify higher prices can be very dangerous. That is how stock market bubbles form.

That is why we need to put the recent price action into proper context. The weekly chart below shows where the plunge to $22.66 fits into the big picture.

Bank of America Elliott Wave pattern coming to an end?

The weekly chart reveals the structure of BAC’s recovery from as low as $4.92 in December, 2011. It can easily be seen as a five-wave impulse, developing within the parallel lines of a trend channel, whose wave (5) has just begun. The five sub-waves of waves (1) and (2) are also clearly visible.

According to the Elliott Wave theory, every impulse is followed by a three-wave correction in the opposite direction. If this count is correct, wave (5) can be expected to lift Bank of America stock to the area between $35 and $40 a share.

Investors are likely going to keep riding this earnings-inspired rally for a while. On the other hand, once wave (5) exceeds the top of wave (3), we should be very careful. The support area of wave (4) near $23 would be a natural target for the anticipated three-wave correction.

2018 was the best year in Bank of America’s history, but the stock finished the year down 17% anyway. Remember that when everything looks rosy near the top of wave (5).

Did you like this analysis? Our Elliott Wave Video Course can teach you how to uncover similar opportunities yourself!

Disclosure: The author holds a long position in BAC stock.

Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Shopify is One of Many Bubble Stocks Out There

It is becoming pretty clear that a speculative bubble is inflating right now. Money-losing companies with market caps in the tens and even hundreds of billions of dollars have become the norm, not the exception. People, who have been in the market for just a couple of months are bragging online about the phenomenal returns…

Read More »

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

More analyses